https://www.fox4news.com/news/no-frozen-wind-turbines-arent-the-main-culprit-for-texas-power-outages
Frozen wind turbines in Texas caused some conservative state politicians to declare Tuesday that the state was relying too much on renewable energy. But in reality, the lost wind power makes up only a fraction of the reduction in power-generating capacity that has brought outages to millions of Texans across the state during a major winter storm.
While Webber said all of Texas’ energy sources share blame for the power crisis, the natural gas industry is most notably producing significantly less power than normal.
"Gas is failing in the most spectacular fashion right now," Webber said.
"It appears that a lot of the generation that has gone offline today has been primarily due to issues on the natural gas system," he said during a Tuesday call with reporters.
Still, some have focused their blame on wind power.
Gas might be failed but wind power failed. Completely. In short, any power in Texas right now is from fossil fuels and it's going to stay that way for a bit.
ReplyDeleteWind power is a failure in general. It's expensive. It's unreliable. It only survives by living on government handouts and a pliant media willing to overlook its failings.
therefore blame it for the failure of natural gas?
ReplyDeletehttps://www.fiercepharma.com/pharma/novavax-heels-coronavirus-shot-data-enters-massive-supply-deal-global-vaccine-consortium
ReplyDeleteTrump warp speed 💪
Novavax - Trump warp speed success
ReplyDeleteNatural gas didn't fail. It was overwhelmed and hampered by poor infrastructure but it is still working in areas.
ReplyDeletethis is relevant to what?
ReplyDeleteWhile Novavax hasn't yet scored emergency authorizations for its vaccine, some market watchers have touted the vaccine's data against other prominent players. After the company posted phase 3 data last month, Evercore ISI analyst Josh Schimmer wrote to clients that he sees Novavax as the "vaccine to beat." The shot features "strong potency and unique tolerability," he added.
ReplyDeleteIn a phase 3 trial in the U.K., the vaccine posted efficacy of 89.3% despite challenges from a new variant circulating there. Efficacy was lower in a separate trial in South Africa.
I can't find the original post where you attacked Trump backing this company which had not yet to date produced a single approved medicine.
ReplyDeleteIt still has not bee approved while others have - this proves what?
ReplyDeleteThey have good data, which they are submitting, so it is effective.
ReplyDeleteJohnson and Johnson also not yet approved, but they have the data.
Proves not to put all your eggs in one basket.
Wow!
ReplyDeleteAnd because of this it has saved 0 lives and prevented 0 people from sick
ness and all because you claim Trump was so wise and foresighted!? spreading lies about the virus and refusing to wear a mask or social distance
Nope, they already tested on 30,000 people. Or half with the true VAX.
ReplyDeleteOther big pharmaceutical companies had problems - Novartis failed and dropped its project.
Before we knew whether or which vaccine strategy would work, thats 1 Year ago, the correct strategy was to encourage and invest in a diverse group of potential vaccines. not just a couple of big pharma names.
ReplyDeleteand Trump alone knew about this?!
ReplyDeleteWhy do you view this as vindication of Trump?
there is no total vindication nor total abject failure regarding Trump.
ReplyDeleteI am talking about project warp speed alone.
If trump was against renewable energy, then it is his failure. if he did something good, then it's to his zchus/ Whehter he is a rasha /beinoni or Tzaddik is a subjective view. Some people can see him do no right, and similarly some can see him do no wrong.
That is not what you initially said!
ReplyDeleteThis vaccine is not a significant player and therefore criticizing giving billions to a company that never made a vaccine is still valid
It is significant, 1.1 billion doses for world distribution is big.
ReplyDeleteIt still has not been approved for use
ReplyDeleteI am not a chozeh, are you?
ReplyDeleteBut it is increasingly likely that they wil be getting approval very soon - that is why they announced their positive data. If the data was poor, they would be kvetching or keeping silent.
https://www.fool.com/investing/2021/02/20/3-green-flags-for-novavax-investors-and-1-red-flag/
No, that criticism is NOT valid. That criticism fails to understand how investment works. They should have invested into multiple companies and multiple vaccine modalities, as they did, because before running the trials no one knew which if any would be successful. As it turns out, it looks like Novavax will be added to the list of successful vaccines *BASED ON ITS TRIAL DATA.* None of them received immediate FDA approval after reporting phase 3 results. If you think JNJ's product isn't getting approved in the next few weeks, I have a bridge to sell you. Novavax will either be approved based on UK phase 3 data or on a combination with its US phase 3 data, the trial for which it just announced completed enrollment, suggesting the interim analysis will come in perhaps the next month or so. The investment from US govt helped Novavax make the adjustments to its manufacturing that FDA required for them to start their US phase 3 program. It started late because of those requirements!
ReplyDeleteOperation Warp speed was not a vaccination program designed for *December 2020 - February 2021*
It's a vaccination program for 2020, 2021 and years into the future and it will help the entire world, not just the US. So who is a "significant player" in the first few months of the vaccination campaign is not the end all and be all. To sum up, they needed to diversify the investment rather than guess and pick only the winners before the biological experiments were done, and JNJ & Novavax cannot anyway be called losers based on their results. Stop the TDS arguments.
Those additional purchases were made because of confidence it will be approved *Based on phase 3 results to date* that were already reported.
ReplyDeletePerhaps you have some hybrid halachic thinking -
ReplyDeletebut just imagine we are at the start line now _ invest in a diverse portfolio of projects both biotech and pharma.
to develop a new drug you must climb a mountain of failures $3bn cumulative costs.